Clinical Trials Browser

INDUSTRY × Sezary Syndrome × 1 year × Clear all

NCT03902184 2026-04-29

TELLOMAK

Phase 2 Completed

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT06854653 2026-04-29

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Phase 2 Recruiting

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT07192471 2026-04-20

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

Phase 1 Not yet recruiting

DermatologicLymphoid

Immune System Diseases, Lymphoma, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07132567 2025-09-22

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Mycosis Fungoides, Sezary Syndrome